Technology
Three proprietary & Differentiated technology platforms enablethe production of pipelines & novel E3L platforms in a persistent & organized manner
We specialize in identifying and validating diseases characterized by unmet medical needs for patients that could not be solved by existing drug paradigms using first-in-class drugs through the targeted protein degradation (TPD) modality. We are dedicated to conducting comprehensive research and development, from initial exploration to clinical trials.
E3 ligases (E3Ls), a crucial element in targeted protein degradation (TPD) new drug development, are present in over 600 types within the body but majority of these remain largely unexplored, with extensive research conducted on only around 10 types. There have been limitations in the application of TPD in new drug development except for the two types of E3 ligases (CRBN and VHL), and we have concentrated our research and development efforts to address this challenge. Accordingly, we have devised a platform technology capable of identifying promising E3 ligases. To date, we have successfully discovered a substantial number of novel E3 ligase binders, and we possess a pipeline.
SpeedUPP™
PROTAC Hit to Candidate : 2 ~ 2.5yrs
Early lead cmpds
Massive in vivo tests / Lead Opt.
Candidate cmpd
PROTAC Hit to Candidate : 2 ~ 2.5yrs
Early lead cmpds
Massive in vivo tests / Lead Opt.
Candidate cmpd
- Enhance a chance to obtain lead compound with favorable drug-like properties
- Develop bifunctional degrader pipelines in a prompt manner
- Degrader designing know-how derived from our experiences of designing / synthesizing / assaying 4,000+ degraders enables us to produce effective degrader compound with high hit ratio.
- 30+ seasoned medicinal chemists facilitate prompt degrader synthesis.
- Our in-house luciferase-based live cell assay platform with the capability to develop knok-in cell lines facilitates high-throughput screening which is challenging to achieve through traditional western blot assays
- Rodent experiment capability in house enables early PK/PD tests to promptly provide clues to following degrader design for a improved drug-like properties.
UPPGRADER™
"UPPGRADER™ is our proprietary solution that precisely discovers promising novel E3Ls with strong scientific rationales mainly based on scRNA-seq. data analysis"
"UPPGRADER™ is our proprietary solution that precisely discovers promising novel E3Ls with strong scientific rationales mainly based on scRNA-seq. data analysis"
UPPGRADER can profile cell subtypes & disease-specific expression level & pattern of novel E3Ls, which is hard to be addressed by most other players doing tissue specific profiling.
UPPGRADER can profile cell subtypes & disease-specific expression level & pattern of novel E3Ls, which is hard to be addressed by most other players doing tissue specific profiling.
UPPBEAT™
"UPPBEAT is a covalent ligand screening platform designed to discover novel ligands for the selected novel E3Ls, leveraging out proprietary probe library & strong chemoproteomics capabilities."
"UPPBEAT can also be utilized to concurrently / simultaneously discover novel E3Ls and their corresponding ligands. (Ligand-first approach)"
"UPPBEAT is a covalent ligand screening platform designed to discover novel ligands for the selected novel E3Ls, leveraging out proprietary probe library & strong chemoproteomics capabilities."
"UPPBEAT can also be utilized to concurrently / simultaneously discover novel E3Ls and their corresponding ligands. (Ligand-first approach)"
"While most other players focus on cysteine for covalent ligand discovery, UPPBEAT, by targeting multiple residues beyond cysteine, widens the hit ratio for novel E3L ligands"
- A state-of-the-art LC-MS/MS in house(Vanquish Neo UHPLC + Orbitrap EclipseTM TribridTM MS) enables to routinely run chemoproteomics to deconvolute novel E3Ls.
- Proprietary covalent probe library which is expanding & organizing enables to approach multiple nucleophilic resdues including Cysteine, Lysine, Tyrosine, Histidine etc.
- Professional team with expertise on covalent ligand screening & chemoproteomics including a inventor of SuTEx (sulfur-triazole exchange chemistry) enables to effectively
"While most other players focus on cysteine for covalent ligand discovery, UPPBEAT, by targeting multiple residues beyond cysteine, widens the hit ratio for novel E3L ligands"
- A state-of-the-art LC-MS/MS in house(Vanquish Neo UHPLC + Orbitrap EclipseTM TribridTM MS) enables to routinely run chemoproteomics to deconvolute novel E3Ls.
- Proprietary covalent probe library which is expanding & organizing enables to approach multiple nucleophilic resdues including Cysteine, Lysine, Tyrosine, Histidine etc.
- Professional team with expertise on covalent ligand screening & chemoproteomics including a inventor of SuTEx (sulfur-triazole exchange chemistry) enables to effectively
